Springhood Ventures

Springhood Ventures is a Boston-based early-stage venture capital firm founded in 2018 by John Parker with a singular mission: to back emerging life science and healthcare companies transforming the health and care of people in their first two decades of life. The firm positions itself as the first venture capital firm broadly dedicated to children's health, investing on a mission-first basis in seed-stage pediatric medical solutions spanning drug discovery, neonatal diagnostics, predictive analytics, and medical devices. The investment thesis targets the intersection of high clinical need, exceptional innovation, and the development incentives unique to the child-health market, including rare pediatric disease vouchers and orphan designations. Founder and Managing Partner John Parker spent 25 years across venture capital, private equity, and hedge funds before launching Springhood. He previously created and managed CH Innovations, the impact-first venture capital subsidiary of the Charles H. Hood Foundation -- a Boston private foundation supporting pediatric research -- where Parker remains a trustee and runs its Program-Related Investment initiative. The portfolio is intentionally concentrated, with four disclosed investments including TMA Precision Health (pediatric precision-medicine risk analytics), FLAG Therapeutics (drug discovery), NeoPrediX (predictive analytics for neonatal, maternal, and perinatal health, the most recent new investment in September 2024), and a prior holding in Novonate, which was acquired by Laborie Medical in February 2023. Springhood's focus on the first two decades of life is both a moral and commercial thesis: pediatric drug development carries regulatory incentives that improve risk-adjusted returns, and the market is underserved by generalist life-science VCs whose portfolio prioritization naturally gravitates toward the larger adult patient populations.